365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial
Yamazaki, K., Tsushima, T., Shitara, K., Sarholz, B., Fujita, M., Doi, T.Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)30228-3
Date:
September, 2015
File:
PDF, 69 KB
english, 2015